Gilead Sciences and Lakefront Biotherapeutics Acquire Ouro Medicines
March 27, 2026
Gilead Sciences agreed to acquire Ouro Medicines to expand its inflammation and immunology pipeline with gamgertamig (OM336), a clinical-stage BCMAxCD3 T cell engager for autoimmune diseases. The deal adds gamgertamig to Gilead’s portfolio and establishes Lakefront Biotherapeutics’ clinical development pipeline, with Lakefront overseeing Phase 1/2 studies and sharing upfront/milestone economics.
- Buyers
- Gilead Sciences, Inc., Lakefront Biotherapeutics
- Targets
- Ouro Medicines
- Industry
- Pharmaceuticals
- Location
- California, United States
- Transaction Type
- Buyout
Explore More
Build a buyer list for your deal
Find active buyers from recent acquisition patterns and move straight into outreach.